News
MIRM
93.77
-0.69%
-0.66
Mirum Pharmaceuticals Price Target Raised to $194.00/Share From $184.00 by Citigroup
Dow Jones · 1h ago
Mirum Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 1h ago
Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $194
Benzinga · 2h ago
Mirum Pharmaceuticals price target raised to $194 from $184 at Citi
TipRanks · 9h ago
Mirum succeeds in second late-stage trial for hepatitis D therapy
Seeking Alpha · 1d ago
Mirum Pharmaceuticals reports primary endpoint met in AZURE-4 Phase 3 study
TipRanks · 1d ago
Mirum Pharmaceuticals' Brelovitug Meets Primary Endpoint In Phase 3 AZURE-4 Study
NASDAQ · 1d ago
Mirum’s Strong Bre-lovitug Profile and Commercial Potential Support a Buy Rating
TipRanks · 1d ago
Mirum Pharmaceuticals Reports Positive Phase 3 Brelovitug Results
TipRanks · 1d ago
Mirum’s Buy Rating Reaffirmed as Breviloitug Shows Durable HDV Suppression; $184 Price Target Unchanged
TipRanks · 1d ago
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
Barchart · 1d ago
Weekly Report: what happened at MIRM last week (1102-1106)?
Weekly Report · 2d ago
Mirum Pharmaceuticals: Strong Commercial Momentum and Pipeline Catalysts Support Unchanged $145 Price Target
TipRanks · 5d ago
Mirum Pharmaceuticals Price Target Cut to $140.00/Share From $154.00 by Leerink Partners
Dow Jones · 5d ago
Mirum Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Dow Jones · 5d ago
Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140
Benzinga · 5d ago
Mirum Pharmaceuticals (MIRM) Receives a Rating Update from a Top Analyst
TipRanks · 6d ago
GeneDx, Mirum launch sponsored testing programs
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Mirum Pharmaceuticals (MIRM)
TipRanks · 6d ago
Data Privacy Risks: How Global Regulatory Pressures Threaten Mirum Pharmaceuticals’ Operations and Profitability
TipRanks · 6d ago
More
Webull provides a variety of real-time MIRM stock news. You can receive the latest news about Mirum Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.